NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate Update
Key Highlights
- ➤Q3 2026 results scheduled for November 17 before market open
- ➤NRx to host an 8:00am ET conference call on November 17
- ➤DARPA awarded NRx an $11.25 million contract for an NRX-101 Phase 3 trial
- ➤NRX-100 received Fast Track designation for suicidal ideation in depression
- ➤NRX-101 received Breakthrough Therapy designation for suicidal bipolar depression
WILMINGTON, Del., Nov. 12, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target depression, PTSD and suicidality, today announced that it will release its third quarter 2026 financial results before the market opens on Tuesday, November 17, 2026 via press release, which will be available on the Company’s website at https://ir.nrxpharma.com/. The Company will host a conference call at 8:00am ET the same day.
A live webcast of the conference call will be available on the Company’s website at https://ir.nrxpharma.com/events. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-800-717-1738 or internationally +1-646-307-1865.
Get started
Create a free account to read the full story.